David M. Swoboda, MD, discusses the roles of available TKIs for the treatment of patients with chronic myeloid leukemia.
David Swoboda, MD
Advertisement
David Swoboda, MD, is the clinical director of leukemia at Tampa General Hospital Cancer Institute and an assistant professor at the University of South Florida Morsani College of Medicine in Tampa.
Articles by David Swoboda, MD
Incorporation of menin inhibitors is central to improving the outcome of difficult-to-treat leukemias.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Palbociclib Plus Trastuzumab, With/Without Pertuzumab, and ET as Maintenance in HR+, HER2+ Metastatic Breast Cancer
2
FDA Approves Sacituzumab Govitecan Monotherapy and In Combination With Pembrolizumab in Frontline TNBC
3
Perioperative Pembrolizumab/Enfortumab Vedotin Approved in Europe for Cisplatin-Ineligible MIBC
4
Iza-Bren Is Approved in China for Recurrent/Metastatic Nasopharyngeal Carcinoma
5